BPC 157 Benefits: What the Evidence Actually Shows

BPC 157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV), described as a fragment of a protein found in human gastric juice. "Pentadecapeptide" just means fifteen residues. It has no marketing approval from the FDA, the EMA, or any comparable regulator, so there is no prescribing information, no approved indication, and no label-sanctioned dose to quote.

Unusually for a peptide, it appears to survive gastric acid, which is why oral, injected and topical routes have all been studied.

Across the animal literature, the same handful of effects recur. The mechanistic account, summarised in a 2025 Current Reviews in Musculoskeletal Medicine scoping review, is that BPC 157 activates VEGFR2 and drives nitric oxide synthesis through the Akt-eNOS axis, engages ERK1/2 signalling, and promotes angiogenesis and fibroblast activity. The HSS Journal review adds increased growth hormone receptor expression and reduced inflammatory cytokines.

The one piece of work done on actual human tissue is worth naming precisely, because it is often overstated. A 2026 study in Journal of Clinical Medicine took leftover internal mammary artery segments from 12 coronary bypass operations and measured how the rings relaxed in an organ bath. BPC 157 produced concentration-dependent vasorelaxation that was largely abolished when nitric oxide synthase was inhibited. That is real evidence that the nitric oxide mechanism operates in human tissue. It is not evidence that anyone got better.

Three pilot studies, plus a pharmacokinetic fragment.

Knee pain (2021). A retrospective chart review at a single Florida clinic. Sixteen of 17 patients were reached by phone; 12 had received BPC 157 alone by intra-articular injection. Eleven of those 12 reported significant improvement. No validated function, stiffness or quality-of-life instrument was used, there was no control group, and follow-up intervals varied. The HSS Journal systematic review characterised the durable result more conservatively: 7 of 12 patients reporting relief beyond six months.

Interstitial cystitis (2024). Twelve women, aged 39 to 76, all of whom had failed pentosan polysulfate, received a total of 10 mg of BPC 157 injected around the inflamed area of the bladder wall during a single cystoscopy. Ten of 12 rated their outcome at 100% on the Global Response Assessment; the other two rated it at 80%. No dropouts, no adverse events reported. Again: no control arm, no blinding, one clinic, one investigator group.

Intravenous safety and pharmacokinetics. A small pilot, described in the 2026 Pharmaceutics review as involving two subjects, consistent with a plasma half-life under 30 minutes.

There is also a registered phase 1 trial (NCT02637284) run by PharmaCotherapia at Hospital Ángeles Tijuana, which planned 42 healthy volunteers taking 1 mg oral tablets, single doses of 1, 3 or 6 tablets and then 3 tablets every 8 hours for two weeks. Its registry status has read "unknown" since 2015 and no results are posted. A registered trial with no published outcome is not evidence of benefit.

Searching ClinicalTrials.gov for BPC-157, "pentadecapeptide" and "body protection compound" turns up two genuine interventional records. Two. That is the entire registered clinical footprint of a compound that has been worked on in animals for three decades.

The first is the 2015 PharmaCotherapia phase 1 described above. Its design was the right shape — randomised, quadruple-blind, placebo-controlled, with adverse events as the primary outcome — but it stalled at "unknown" status in December 2015 and has never posted a result.

The second, NCT07752381, is the only record marked completed. Parlay Wellness enrolled 40 physically active adults who took two "Parlay Recover" gummies daily for eight weeks, each serving containing 500 µg of BPC-157. Its primary outcomes are change in hs-CRP and interleukin-6 between baseline and week 8, alongside self-reported swelling. It is single-arm and unmasked, with no control group and no placebo, so whatever it recorded cannot be separated from time, training load or expectation. It finished in November 2025 and, as of the record's last update in August 2026, no results have been posted.

That leaves a very specific hole. No study exists anywhere in the registry that is capable of separating BPC 157 from placebo and from rehabilitation — none recruiting, none completed, none planned. There is no pending readout, no date to wait for, and no dose-finding work in progress that would produce a defensible human number. Three decades into the preclinical programme, that absence is the most informative fact on this page.

This is where a benefits list collides with arithmetic, and it is the part most articles skip.

The Zagreb group that produced much of the preclinical corpus typically dosed rats at 10 µg/kg/day and 10 ng/kg/day — and reported comparable healing effects at both. That is a thousand-fold span with the same reported outcome. A dose range that wide is a sign the studies were designed to demonstrate an effect, not to find a dose.

Scaled naively by body weight, 10 µg/kg in a 70 kg adult is 0.7 mg/day, and 10 ng/kg is 0.7 micrograms/day. Neither figure is a human dose. Interspecies conversion is done by body surface area, not body weight, which pushes the equivalent lower still, and no regulator has ever accepted such a conversion for this compound. Meanwhile the vials sold online are typically 5 mg or 10 mg of lyophilised powder, so the container itself spans several orders of magnitude of the published animal exposures.

The pharmacokinetics compound the problem. A rat and beagle ADME study found an elimination half-life under 30 minutes with linear kinetics, and absolute intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs. Excretion was via urine and bile, with the peptide broken into small fragments and then free amino acids. A sub-30-minute half-life sitting alongside claimed effects lasting days is exactly the disconnect the 2026 Pharmaceutics review flags as the central unsolved problem: nobody knows what exposure is supposed to produce the benefit, so nobody can specify a regimen.

If you are working through the mechanics anyway, our BPC-157 dosage reference sets out what the literature reports rather than what to do, the BPC-157 reconstitution calculator handles the mg-to-unit conversion, and the reconstitution guide and syringe measurement guide cover the arithmetic that causes most real-world errors. How much of anything to use, and whether to use it at all, is a decision for a prescriber who knows your history. Nothing on this page is a dosing instruction.

BPC 157 is not approved anywhere. In the United States it has been evaluated as a bulk drug substance for pharmacy compounding under section 503A. The FDA convened its Pharmacy Compounding Advisory Committee on 23-24 July 2026 (docket FDA-2025-N-6895) to consider BPC-157 free base and BPC-157 acetate for the 503A Bulks List. The use the FDA reviewed was ulcerative colitis — not tendon healing, not joint pain. KPV, TB-500 and MOTS-C were on the same agenda. I could not verify the committee's vote or the FDA's final determination from a primary source, so treat the outcome as unresolved here.

In sport, BPC 157 is prohibited by WADA under S0, Non-Approved Substances, which covers substances with no current approval for human therapeutic use. That prohibition applies at all times, in and out of competition, and there is no threshold below which it does not.

The Sports Medicine review by Mendias and Awan places BPC 157 in a "grey market" of unapproved peptides sold direct to patients, notes that rigorous human safety data are scarce, and specifically raises the placebo effect amplified by social media as a mediator of perceived benefit. The HSS Journal authors were blunter: preclinical safety studies showed no adverse effects across several organ systems, and "no clinical safety data were found." Absence of reported harm in rats is not a safety record.